Global Adenomyosis Drugs Market - Industry Trends and Forecast to 2029

Segmentation

Short Description
Global Adenomyosis Drugs Market, By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others),  Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others),  Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest Of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Peru, Rest Of South America, South Africa, Egypt, Israel, UAE, Kuwait And Rest Of Middle East And Africa), Industry Trends And Forecast To 2029

Market Definition:

Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.
The drugs used for the treatment of adenomyosis generally include anti-inflammatory drugs and hormonal drugs such as gonadotropin-releasing hormone analogs (Gnrh Analogs), estrogen-progestin, selective progesterone receptor modulators (SPRMs) or progestin, aromatase inhibitors, and gonadotropin-releasing hormone antagonist, among others. Some of these drugs are used to reduce adenomyotic lesion size and improve the patients dysmenorrhea and quality of life.
Market Segmentation:
The global adenomyosis drugs market is categorized into six notable segments based on type, treatment, patient type, dosage form, end user, and distribution channel.

 On the basis of type, the adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic, and others
 On the basis of treatment, the adenomyosis drugs market is segmented into hormone medications, anti-inflammatory drugs, and others
 On the basis of patient type, the adenomyosis drugs market is segmented into adult, geriatric, and adolescence
 On the basis of dosage form, the adenomyosis drugs market is segmented into parenteral, oral, and others
 On the basis of end user, the adenomyosis drugs market is segmented into hospitals, clinics, specialty center, home healthcare, ambulatory centers, and others
 On the basis of distribution channel, the adenomyosis drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others


Market Players

Some of the major players operating in the global adenomyosis drugs market are:

 Mayne Pharma Group Limited
 Accord Healthcare
 Tolmar Pharmaceuticals, Inc.
 Boehringer Ingelheim International GmbH
 TerSera Therapeutics LLC
 Ferring B.V.
 Lannett
 Par Pharmaceutical (A Subsidiary of Endo International plc)
 Hikma Pharmaceuticals PLC
 Context Therapeutics Inc.
 Viatris Inc.
 Bayer AG
 Teva Pharmaceutical Industries Ltd.
 AstraZeneca
 Pfizer Inc.
 Zydus Pharmaceuticals, Inc.
 Sun Pharmaceutical Industries Ltd
 AbbVie Inc.
 Abbott
 GlaxoSmithKline plc.
 Novartis AG
 Amneal Pharmaceuticals LLC
 Johnson & Johnson Services, Inc.
 Sanofi
 Dr. Reddys Laboratories Ltd.

Methodology